Navigation Links
Breast cancer risk varies among different progestins used in hormone replacement therapy
Date:8/10/2010

COLUMBIA, Mo. Progestins are used in hormone replacement therapies to counteract the negative effects of estrogen on the uterus and reduce the risk of uterine cancer. However, evidence in recent studies and clinical trials has demonstrated that progestins increase the risk of breast cancer. Now, University of Missouri researchers have compared four types of progestins used in hormone replacement therapies and found significantly different outcomes on the progression of breast cancer in an animal model depending on the type of progestins used.

"Synthetic progestins have different biological effects, due to differences in their structure, stability and how they interact in the body," said Salman Hyder, the Zalk Endowed Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center. "Clinical use of progestins requires caution. These powerful steroids should only be prescribed when a person has no latent, or dormant, cancer and does not have a family history of cancer. However, it is difficult to diagnose latent tumor cells in women since there are no symptoms."

In the study, researchers compared the effects of four clinically relevant progestins on breast cancer tumors in an animal model. The progestins used in the study were the synthetic progestin medroxporgresterone acetate (MPA), norgesterel (N-EL), norethindrone (N-ONE) and megestrol acetate (MGA). In the United States, most women on hormone replacement therapy are treated with MPA, the progestin in Prempro, Hyder said.

"Although previous studies using an animal model for breast cancer found that MPA functions as a tumor promoter, this study show that N-EL and N-One, when administrated using the same protocol as used for MPA, strongly inhibited tumor development," Hyder said. "Thus progestins seem to have tumor-stage specific effects, which determine whether these will function as tumor promoters or tumor suppressors. Progestins, such as N-EL and N-ONE, may have potential as preventive agents in women with no history of breast disease or family history of breast cancer. These progestins may also have a preventive role in post-menopausal women who are at an increased risk for developing breast cancer due to ingestion of combined estrogen/progestin (MPA) hormone replacement therapy and may have early stage disease."

The chart below shows the tumor latency and tumor incidence for the four types of progestins. Tumor latency is the period from when the animal model is first exposed to tumor cells to the first signs of cancer.


'/>"/>

Contact: Steven Adams
adamsST@missouri.edu
573-882-8353
University of Missouri-Columbia
Source:Eurekalert

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 10, 2016 , ... The Journal of Pain Research has ... field .” , As corresponding author Dr John F. Peppin says “Terminology matters, yet ... our chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... service to expand access to affordable hearing aids , increase industry transparency, ... individuals in the United States. , “For the average consumer, the hearing aid ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
(Date:2/9/2016)... California (PRWEB) , ... February 09, 2016 , ... i2i ... one of the highest preliminary data vendors in the latest KLAS report, Population Health ... i2i has led the developing market for population health management (PHM). The latest ...
(Date:2/8/2016)... N.J. (PRWEB) , ... February 08, 2016 , ... ... cancer patients, has officially launched the Multiple Myeloma Heroes Awards event , which ... or in the lives of patients with MM. The MM Heroes Awards nomination ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... , Feb. 9, 2016 The new report "Global ... Acuity Business Research & Consulting group reveals that the ... with a share of 38.9% in 2014 that translated into revenues ... , Europe , Asia-Pacific , ... and Africa . The global anti-bacterial market is ...
(Date:2/8/2016)... Cardiac Assist Devices - ... GlobalData,s Medical Devices sector report, " Cardiac Assist ... provides an overview of Cardiac Assist Devices currently ... information on the pipeline products with comparative analysis ... The report reviews major players involved in the ...
(Date:2/8/2016)... Cardiovascular Surgery Devices - Medical Devices ... Devices sector report, "Cardiovascular Surgery Devices - Medical ... Cardiovascular Surgery Devices currently in pipeline stage. ... report provides comprehensive information on the pipeline products ... stages of development. The report reviews major players ...
Breaking Medicine Technology: